CXCR4 and lymphoma: In this regard, CXCR4-targeted radioligand therapy (RLT) based on pretherapeutic PET/CT has already achieved outcome benefits in end-stage lymphoma patients [5, 18, 19], thereby rendering this theranostic concept favorable for the referring hemato-oncologist [6].